HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of melasma with the 1,927-nm fractional thulium fiber laser: a retrospective analysis of 20 cases with long-term follow-up.

AbstractBACKGROUND:
Melasma is a common acquired symmetrical hyperpigmentation that is often recurrent and refractory.
OBJECTIVES:
To investigate the efficacy and safety of a single administration of high-density fractional thulium fiber laser (1,927 nm) for the treatment of refractory melasma in 20 patients.
MATERIALS AND METHODS:
A retrospective chart and photographs review of 20 women (Fitzpatrick skin type II-IV) with clinical diagnosis of melasma treated with the 1,927-nm fractionated thulium laser at 10 or 20 mJ/cm(2) , with 60-70% surface area coverage. Four investigators independently evaluated Melasma Area Severity Index (MASI) scores before, 4 weeks, 3-6 months, and 6-12 months after treatment.
RESULTS:
Mean MASI scores decreased dramatically from 13.2 ± 5.4 before treatment to 8.5 ± 3.5 at 4 weeks after laser treatment (P = 0.004). Patient assessment revealed that 12 of the 20 subjects had more than 50% clearance of their melasma. Recurrence was reported by 7 out of 15 patients who were successfully followed-up (mean 10.2 months). Two patients developed postinflammatory hyperpigmentation that subsided with topical bleaching after 3 months.
CONCLUSION:
High-density coverage fractional 1,927-nm thulium laser proved to be safe and effective for melasma with long-term remission.
AuthorsAne Beatriz M Niwa Massaki, Sasima Eimpunth, Sabrina G Fabi, Isabella Guiha, William Groff, Richard Fitzpatrick
JournalLasers in surgery and medicine (Lasers Surg Med) Vol. 45 Issue 2 Pg. 95-101 (Feb 2013) ISSN: 1096-9101 [Electronic] United States
PMID23255085 (Publication Type: Evaluation Study, Journal Article)
CopyrightCopyright © 2012 Wiley Periodicals, Inc.
Topics
  • Adult
  • Female
  • Follow-Up Studies
  • Humans
  • Lasers, Solid-State (therapeutic use)
  • Melanosis (surgery)
  • Middle Aged
  • Patient Satisfaction
  • Retrospective Studies
  • Severity of Illness Index
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: